Briumvi (ublituximab-xiiy) is a prescription drug that’s used to treat certain types of multiple sclerosis (MS) in adults. Briumvi is given as an intravenous (IV) infusion by a doctor or other ...

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained ...

Briumvi is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary ...

Learn more› By Zoe Vanderweide and Justin Krajeski One of our picks, the Uniqlo Supima Cotton Crew Neck T-Shirt, has been redesigned; it’s now slightly longer, roomier, and more opaque.

September 2024 A button-up shirt may be your closet’s stealthiest chameleon, equally at home in a blue-chip law firm, an oonz-oonz dance club, and a Sunday farmers market. But this undeniable ...

TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials, evaluating BRIUMVI. The data showed that continued use of BRIUMVI resulted ...

(RTTNews) - TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The company said the data ...

The trials evaluated BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) over five years. The presentations highlighted the long-term efficacy and safety of ...

The trials evaluated BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) over five years. The presentations highlighted the long-term efficacy and safety of BRIUMVI ...